Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/88671
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBeltrame, J.-
dc.contributor.authorGanz, P.-
dc.contributor.editorKaski, J.-
dc.contributor.editorEslick, G.-
dc.contributor.editorBairey Merz, C.-
dc.date.issued2013-
dc.identifier.citationChest pain with normal coronary arteries: a multidisciplinary approach, 2013 / Kaski, J., Eslick, G., Bairey Merz, C. (ed./s), vol.9781447148388, Ch.10, pp.101-117-
dc.identifier.isbn1447148371-
dc.identifier.isbn9781447148371-
dc.identifier.urihttp://hdl.handle.net/2440/88671-
dc.descriptionCopyright © 2007 Elsevier B.V. All rights reserved.-
dc.description.abstractThe coronary slow flow phenomenon (CSFP) is a microvascular coronary disorder, ­characterised angiographically by delayed contrast opacification of the distal vasculature in the absence of obstructive coronary artery disease. Its prevalence has been reported as 1–3 % of coronary angiograms performed. It often presents initially as an acute coronary syndrome with 8 % of patients having positive cardiac markers for myocardial infarction. Although transient T wave changes are frequently observed during the acute episode, only a third of patients have clinical evidence of inducible myocardial ischaemia. Both structural and functional studies have demonstrated the presence of microvascular coronary dysfunction however the underlying cause remains elusive. Possible pathogenetic mechanisms include a defective endothelial nitric oxide pathway, excessive endothelin mediated vasoconstriction, autonomic dysfunction, platelet dysfunction, metabolic derangements (associated with the metabolic syndrome and hyperhomocystinaemia), and vascular inflammation. The risk of future cardiac events following the initial presentation appears low however many patients continue to experience recurrent chest pain. Further well-controlled therapeutic studies are required to identify effective therapies for this disabling condition.-
dc.description.statementofresponsibilityJohn Beltrame and Peter Ganz-
dc.language.isoen-
dc.publisherSpringer London-
dc.rights© Springer-Verlag London 2013-
dc.source.urihttp://dx.doi.org/10.1007/978-1-4471-4838-8_10-
dc.subjectCoronary slow flow phenomenon-
dc.subjectMicrovascular coronary dysfunction-
dc.subjectSlow flow-
dc.subjectSyndrome X-
dc.subjectSyndrome Y-
dc.subjectMicrovascular angina-
dc.subjectCoronary heart disease-
dc.subjectNormal angiogram-
dc.subjectMibefradil-
dc.subjectNebivolol-
dc.subjectTrimetazidine-
dc.subjectStatins-
dc.subjectDipyridamole-
dc.subjectEndothelin-
dc.subjectEndothelial dysfunction-
dc.subjectCoronary flow reserve-
dc.subjectMicrovascular disease-
dc.titleThe coronary slow flow phenomenon-
dc.typeBook chapter-
dc.identifier.doi10.1007/978-1-4471-4838-8_10-
dc.publisher.placeUSA-
pubs.publication-statusPublished-
dc.identifier.orcidBeltrame, J. [0000-0002-4294-6510]-
Appears in Collections:Aurora harvest 7
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.